跳至主要内容
临床试验/NCT05971407
NCT05971407已完成不适用

The Effect of Chronic Remote Ischaemic Preconditioning on Blood Pressure in Older Adults

University of Nottingham2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年9月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
Clinic systolic blood pressure

研究概览

简要总结

The purpose of this study is to assess whether remote ischaemic conditioning, applied chronically, improves vascular health in older adults

详细描述

Hypertension and stroke remain leading causes of mortality across the world (1). Hypertension affects more than 1 in 4 adults and is the 3rd biggest risk factor for premature death and disability in the UK (2). Cerebrovascular disease is ranked 4th in the list of leading causes of death in the UK (3). At present, the treatment of these conditions largely involves chronic pharmacotherapy. In parallel, it is increasingly appreciated that polypharmacy poses a significant challenge to our older adult population. Guthrie et al showed that the number of people prescribed >5 medications in an area of the UK doubled between 1995 and 2010 (from 11.4% to 20.8%) (4). Age is significantly associated with polypharmacy, with an odds ratio of 118.3 when those aged 20-29 are compared to those >80. What's more, it has been estimated that adverse drug reactions account for 6.5% of hospital admissions (5), with age correlating significantly with admissions for this reason. Therefore, discovering a non-pharmacological intervention for hypertension and cerebrovascular disease could greatly benefit the population, particularly the elderly, both in terms of treating the diseases themselves and reducing the harmful effects of polypharmacy.

Remote ischaemic preconditioning (RIPC) is the induction of non-lethal ischaemia in one organ or tissue, with the aim of conditioning a distant organ or tissue against ischaemic events. It is achieved via inflation of a blood pressure cuff to supra-systolic pressures for a short period of time. A recent meta-analysis showed that chronic RIC, but not acute RIC, significantly lowered diastolic and mean arterial blood pressure (6). The studies included in this review were small and performed in a younger population, hence larger studies are needed to clarify the effect of RIC in the field of hypertension and, importantly, the elderly.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

盲法说明

Participants are blinded to intervention. Assessors measuring outcomes are blinded to participant identity and intervention.

入排标准

年龄范围
65 Years 至 85 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant is aged >65y and <85y.
  • Participant is willing and able to give informed consent for participation in the study.
  • Participant is physically able to perform RIPC.

排除标准

  • A BMI <18 or >35 kg/m2
  • Active cardiovascular, cerebrovascular or respiratory disease: e.g. uncontrolled hypertension (BP > 160/100), active angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event, COPD, pulmonary hypertension or recent (6 mo) stroke.
  • If history of hypertension, no recent alteration to antihypertensive medication (3 months).
  • A history of, or current neurological or musculoskeletal conditions (e.g. epilepsy)
  • Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

结局指标

主要结局

Clinic systolic blood pressure

时间窗: Measured at baseline, week 3 and week 6

Changes in blood pressure measured by automated sphygmomanometer over 6 weeks. Measured after participants have rested for 10 minutes in a temperature controlled room.

次要结局

  • Clinic Mean arterial pressure(Measured at baseline, week 3 and week 6)
  • 24-hour diastolic blood pressure(Measured at baseline and week 6)
  • Clinic diastolic blood pressure(Measured at baseline, week 3 and week 6)
  • 24-hour systolic blood pressure(Measured at baseline and week 6)
  • 24-hour mean arterial pressure(Measured at baseline and week 6)
  • Flow mediated dilatation (FMD)(Measured at baseline, week 3 and week 6)
  • Pulsewave velocity (PWV)(Measured at baseline, week 3 and week 6)
  • Serum biomarkers(Measured at baseline and week 6.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Bethan Phillips

Professor

University of Nottingham

研究点 (2)

Loading locations...

相似试验

The Effect of Chronic Remote Ischaemic... | 临床试验